PPARA and hydrops fetalis: Fenofibrate, a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, exhibits potent lipid-modifying effects, including reduction of triglycerides and elevation of HDL-C levels.19 Fenofibrate has demonstrated possible beneficial effects on HF-related outcomes.